Resveratrol for Patients With Colon Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

December 31, 2008

Study Completion Date

April 30, 2009

Conditions
Colon CancerCancer
Interventions
DRUG

Resveratrol

Patients were randomly assigned to one of four dose cohorts: plant-derived resveratrol tablets (purchased through the Life Extension Foundation, Scottsdale, AZ) at a dose of 80 mg/day, plant-derived resveratrol tablets at a dose of 20 mg/day, Grape Powder (GP) dissolved in water and taken orally (supplied by the California Table Grape Commission) at a dose of 120 g/day, and GP at a dose of 80 g/day.

Trial Locations (1)

92868

Chao Family Comprehensive Cancer Center, Orange

All Listed Sponsors
collaborator

University of California, Los Angeles

OTHER

lead

University of California, Irvine

OTHER

NCT00256334 - Resveratrol for Patients With Colon Cancer | Biotech Hunter | Biotech Hunter